Dr. Elyse Watkins
Purpose: The purpose of this article is to review pharmacotherapy options for the treatment of overweight and obesity.
Method: A PubMed literature search was conducted with search terms including pharmacotherapy, obesity, anti-obesity drugs/medications, Benzphetamine, Diethylpropion, Phendimetrazine, Phentermine, Orlistat, Alli, Xenical, Liraglutide, Saxenda, Semaglutide, Wegovy, Gelesis, Plenity, Phentermine-topiramate, Qsymia, Bupropion-naltrexone, Contrave, Global Obesity, Global Overweight, US obesity, US overweight. Twenty-three articles are identified as pertinent for this review.
Results: Four single-therapy agents are available for short-term weight loss. Four single-therapy and two combination-therapy medications are FDA approved for long-term weight loss management.
Conclusion: Benzphetamine, Diethylpropion, Phendimetrazine, and Phentermine are four short-term therapies approved for use for 12 weeks. Orlistat, Liraglutide, Semaglutide, Gelesis, Phentermine-topiramate, and Bupropion-naltrexone are FDA approved for long-term use for weight loss.
Davis LA. The Skinny on Treating Adult Obesity: Prescribing for Weight Loss. Lynchburg Journal of Medical Science. 2022; 4(2).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.